Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 31Neoplasms 8Endometrial Neoplasms 6Neoplasm Metastasis 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Meningioma 3Glioblastoma 3Sarcoma 2Pancreatic Neoplasms 2Oligodendroglioma 2Lymphoma, Non-Hodgkin 2Carcinoma, Non-Small-Cell Lung 2Urologic Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Retinoblastoma 1Recurrence 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms, Squamous Cell 1Neoplasm, Residual 1Multiple Myeloma 1

Interventions

lutetium Lu 177 dotatate 2copper dotatate CU-64 2Etoposide 2zimberelimab 1folfirinox 1famitinib 1cabozantinib 1abemaciclib 1Temozolomide 1Nivolumab 1Lutetium-177 1Lutetium 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Cytokines 1Cryotherapy 1Copper 1Cisplatin 1Carboplatin 1Acupuncture Therapy 1Acupressure 164Cu-DOTATATE 1177Lu-octreotide, DOTA(0)-Tyr(3)- 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastro-enteropancreatic neuroendocrine tumor × abemaciclib × Clear all
NCT03891784 2026-01-14

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

University of Washington

Phase 2 Active not recruiting
20 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡